DermWire | Newest Articles Newest Articles en-us Wed, 29 Mar 2017 18:55:55 GMT Wed, 29 Mar 2017 18:55:55 GMT DermWire FDA Approves New Eczema Drug Dupixent The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids. Dupixent is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two key proteins, I… Tue, 28 Mar 2017 04:00:00 GMT Allergan and Paratek Pharmaceuticals' Acne Drug Performs Well in Phase 3 Trials Allergan and Paratek Pharmaceuticals, Inc.’s investigational acne drug performed well in two Phase 3 studies, the companies report. Sarecycline, a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne in the community setting, met its 12-week primary efficacy endpoints. Allergan plans to file a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) in the second h… Mon, 27 Mar 2017 04:00:00 GMT Study: Severe Psoriasis More Common in Men Severe psoriasis predominantly affects men, according to a new study in the American Journal of Clinical Dermatology. In the study of 5,438 Swedish psoriasis patients, women had significantly (p<0.001) lower median Psoriasis Area Severity Index (PASI) values than men (5.4 for women versus 7.3 for men), and this held across all ages and in all areas of the body except for the head. The study found no differences between women and men in the use of medications before enrolment in the registe… Fri, 24 Mar 2017 04:00:00 GMT FDA Approves First Treatment for Rare Form of Skin Cancer The FDA granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. "While skin cancer is one of the most common cancers, patients with a rare form called Merkel cell cancer have not had an approved treatment option until now,… Fri, 24 Mar 2017 04:00:00 GMT Positive Results Announced from SebuDerm Gel Study in Treatment of Seborrheic Dermatitis The results of a clinical study evaluating the impact of Sonoma Pharmaceuticals, Inc.'s SebuDerm (topical hypochlorous acid) gel in the treatment of mild to moderate facial and scalp seborrheic dermatitis were presented at the 13th Annual Maui Dermatology Conference in Maui, HI. In a 25-patient study, conducted by Zoe Draelos, MD, president of Dermatology Consulting Services in High Point, NC, two key metrics were utilized in assessing efficacy of SebuDerm; the first being the investigato… Wed, 22 Mar 2017 04:00:00 GMT No Antibiotics Needed For Mild Infected Eczema in Kids Oral or topical antibiotics are not effective for treating milder clinically infected eczema in children, a new study shows. In the study of 113 children with clinical, non-severely infected eczema, participants received either oral and topical placebos (control), oral antibiotic (flucloxacillin) and topical placebo, or topical antibiotic (fusidic acid) and oral placebo, for one week. All children also received standard eczema treatment with steroid creams and emollients. There were no sig… Mon, 20 Mar 2017 04:00:00 GMT Education Credits Available: ABCs of Nitric Oxide in the Skin A free, online educational program intended to provide participants increased knowledge regarding the role of NO in maintaining a variety of physiologic processes has been launched. The program is directed by James Q. Del Rosso, DO. The program is also intended to address the correlation of NO with the pathophysiology of skin diseases and the role of emerging topical treatments that incorporate NO. Physicians can earn a maximum of 0.50 AMA PRA Category 1 Credit(s)TM and Nurses can earn 0.50 … Mon, 20 Mar 2017 04:00:00 GMT 5α-Reductase Inhibitors Not Associated with Increased Suicide Risk in Older Men Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men, according to new research in JAMA Internal Medicine. Risks for self-harm and depression were increased during the 18 months after medication initiation, although “the relatively small magnitude of these risks should not dissuade physicians from prescribing these medications in appropriate patients,” the study authors report. Concerns have been raised about potential psyc… Mon, 20 Mar 2017 04:00:00 GMT FDA Approved Juvéderm Vollure XC for Correction of Facial Wrinkles and Folds The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months. Patient satisfaction in the pivotal study was also high with 82 percent of patients reporting that they were very satisfied at 6 months and 68 percent at 18 months. … Mon, 20 Mar 2017 04:00:00 GMT Topix Pharmaceuticals Rolls Out Replenix RetinolForte Treatment Serum Topix Pharmaceuticals is adding Replenix® RetinolForte Treatment Serum to their portfolio of offerings. The serum’s patent-pending, time-released Micropolymer delivery system deposits retinol into the skin so patients get the full dosage without the irritation commonly associated with a retinoid. RetinolForte's Micropolymer delivery system stabilizes the retinol to protect its potency, and shields it from oxidation while on the skin. Moreover, the time-released delivery creates… Fri, 17 Mar 2017 04:00:00 GMT Heliocare Spotlights Improved Formulation: Vegan, Gluten-free, and Dye-free Heliocare Daily Use Antioxidant Formula, a clinically proven, natural dietary supplement with antioxidant effects on the skin, has been updated to be vegan, gluten-free, and free of artificial dyes. The once-daily capsules from Ferndale Healthcare, have been recommended by dermatologists for more than two decades and feature Fernblock® PLE Technology, an exclusive antioxidant extract to promote younger-looking skin. Fernblock® PLE Technology is naturally derived from the extract of Po… Fri, 17 Mar 2017 04:00:00 GMT Dermalogica's Newest Add Targets Tired Eyes Dermalogica is launching their newest product -- a two-in-one eye masque that targets tired eyes. The Stress Positive Eye Lift officially launches in early April 2017. Put on with a cooling massage applicator, this masque reduces the appearance of puffiness and dark circles, brightens and lifts the eye area, and helps restore the skin barrier with such ingredients s as wild indigo seed, sea water extract and arctic algae, fermented yeast, a hyaluronic acid blend and bioactive diglucosyl … Thu, 16 Mar 2017 04:00:00 GMT AAD Throws Some Shade At 26 Schools With 2017 Shade Structure Grants The American Academy of Dermatology (AAD) awarded shade structure grants to 26 schools and non-profit organizations across the country. Since its launch in 2000, the AAD’s Shade Structure Grant Program has awarded 350 shade structure grants, which provide shade for more than 600,000 individuals each day. The AAD awarded its 2017 AAD Shade Structure grants to: Alabama Douglas Elementary School, Douglas, Alabama Sponsored by Joshua B. Wharton, MD, FAAD Arizona Donaldson … Thu, 16 Mar 2017 04:00:00 GMT RepliCel’s Baldness Cure Performs Well In First In-Human Trial The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup cells (DSCC) and then re-injecting them back into their scalp. Next up are phase II trials as the new treatment continues its march toward potential commercialization. The five-year trial data set has con… Tue, 14 Mar 2017 04:00:00 GMT Survey Findings: Submental Region Major Pain Point for Patients Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc. The findings were presented at the American Academy of Dermatology (AAD) Meeting in Orlando, FL. The new survey included 1,996 men and women in the U.S. between the ages of 18 and 65. Fully 47 percent reported being bothered by the appearance of the area underneath their chin, and 49 percent said t… Tue, 14 Mar 2017 04:00:00 GMT ADAM Names Lori Skraba 2017 Practice Manager of the Year The Association of Dermatology Administrators and Managers (ADAM) named Lori Skraba of DuBois Dermatology and Cosmetics in DuBois, Pa., the recipient of the annual Practice Manager of the Year award. She was recognized at the 25th annual ADAM meeting in Orlando, FL. The ADAM Practice Manager of the Year award, made possible in collaboration with CareCredit, recognizes a top professional from the organization who best demonstrates outstanding leadership qualities, management skills and consiste… Tue, 14 Mar 2017 04:00:00 GMT Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc. Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the Valeant board until the upcoming annual meeting but will not stand for re-election. At its current market value, the Valeant position represented 1.5% to 3% of the various Pershing Square funds; howeve… Tue, 14 Mar 2017 04:00:00 GMT A “C” Change: Introducing Exuviance’s New Vitamin C Serum Capsules Coming this summer, Exuviance’s AF Vitamin C20 serum capsules promise maximum delivery of actives. Unlike many existing products, Exuviance AF Vitamin C20 Serum comes in capsule form. Other types of packaging expose vitamin C to light, air, or water and threatens stability and effectiveness, but the new capsules maintain maximum strength 20% Vitamin C to boost collagen production, brighten and prevent dark spots and protect against daily environmental damage. In addition, Exuviance-pate… Fri, 10 Mar 2017 04:00:00 GMT Seventeen Percent of Teens Report Excessive Sweating More teens than previously thought may experience excessive, uncontrollable sweating, according to data collected by International Hyperhidrosis Society researchers and presented at the recent American Academy of Dermatology’s (AAD) 2017 Annual Meeting. In the study, seventeen percent of teens reported excessive sweating. By contrast, prior studies put such prevalence at only 1.6 percent to 2.1 percent, the researchers point out. What’s more, three-quarters of participants indi… Fri, 10 Mar 2017 04:00:00 GMT Serlopitant May Stop the Itch of Prurigo Nodularis Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key secondary endpoints. There are no currently approved treatments for prurigo nodularis, The 127-subject multi-center, randomized, placebo-controlled, trial evaluated treatment with once-daily, orally administered serlopitant 5 mg tablets compared with placebo for 8 weeks. … Thu, 9 Mar 2017 04:00:00 GMT New Biomarker May Help Guide Metastatic Melanoma Treatment Decisions Measuring levels of Bim -- a protein made by cancer-fighting T cells -- via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error associated with new immunotherapy drugs. Haidong Dong, M.D., Ph.D., currently a Cancer Research Institute CLIP investigator, and Svetomir Markovic, M.D., Ph.D., who was a CRI clinical investigator from 2002-2007, b… Wed, 8 Mar 2017 04:00:00 GMT New Research Closes In On Personalized AD Therapy New research on skin lipids may pave the way toward personalized therapies for atopic dermatitis. Researchers can now identify the precise lipids found in the skin of people who have atopic dermatitis, and compare them to people with healthy skin. Here’s how: A type of tape can pull some lipids off a person’s skin; allow testing of them with the use of a mass spectrometer; and have the results compared to the skin lipid profiles of generally healthy patients. With this informat… Tue, 7 Mar 2017 04:00:00 GMT Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBS In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annual Meeting in Orlando. There are currently no approved treatment options for EBS, which is the most common form of epidermolysis bullosa. The investigational diacerein 1% ointment (CCP-020), under developm… Mon, 6 Mar 2017 04:00:00 GMT Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humira Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. The primary endpoint of the study was the proportion of patients who achieved a 75 percent improvement at Week 16, as measured by the Psoriasis Area and Severity Index (PASI). Data from the study confirmed equivalent efficacy by demonstrating PASI 75 response rates of 67 percent for proposed biosim… Mon, 6 Mar 2017 04:00:00 GMT Mosquito Virus Expert Discusses a Promising New Drug For Zika Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill viruses or inhibit their capability to reproduce. Voss estimates that a vaccine could be still three to five years away from being licensed and available to patients. Potentially, antiviral drugs to figh… Mon, 6 Mar 2017 04:00:00 GMT